Copenhagen, Denmark – 11 May 2020 – Monsenso has published today a company description detailing the company’s share offer and its plans to trade on Nasdaq First North Growth Market Denmark.
Monsenso’s mobile health solution for mental health is going public, and private Danish investors are invited to participate in Monsenso’s global expansion.
With a scalable and highly sought-after solution within mobile healthcare, Danish company Monsenso has managed to deliver growth in revenue, increase the number of customers, and deliver profits. Now the success must continue globally, which is why Monsenso decided to list on Nasdaq First North Growth Market Denmark. This will allow Danish private investors to join Monsenso’s global expansion of a clinically validated and certified mobile health solution.
The Monsenso mHealth solution has improved the treatment and quality of life for thousands of people affected by mental illness. It has estimated that the number of potential users in Europe alone, is 125 million people, who are affected by mental illness every year. The solution hits a market for mobile healthcare solutions, which is expected to increase on average 40% per year during the upcoming years.
Thomas Lethenborg, CEO of Monsenso, says:
“Our decision to go public has brought positive response both from customers, potential investors, and from the entire team, who has worked hard to get here. I am particularly pleased with the support; we have received from the 40 investors who have made prior commitments to buy shares. This includes Monsenso’s management, the board and employees, who have decided to be co-investors on the journey that we are now beginning.
We have succeeded in establishing ourselves as a strong player in new exciting markets, and now we can develop the company further for the benefit of our users, customers, employees, as well as our shareholders.
The planned IPO is an important milestone in Monsenso’s development. The IPO gives the company a stronger foundation for the continued development of its solution as well as a stronger sales and support set-up. It strengthens Monsenso’s potential to grow in mHealth market, which is expected to grow significantly during the upcoming years”.
The Company Description, the brochure, as well as further information is available for Denmark-based investors on www.monsenso.com/investors and potential investors can register for one of the virtual investor meetings on www.monsenso.com/ipo.
For more information:
Monsenso
CEO Thomas Lethenborg
Tel: +45 21 29 88 27
E-mail: Lethenborg@monsenso.com